Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 29, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

November 30, 2025

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

DRUG

HSK39297 tablets

oral

DRUG

HSK39297 tablets

oral

DRUG

HSK39297 tablets

oral

Trial Locations (1)

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY